Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy Followed by Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma: pCOLA

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This is multicentric, single-arm, observational, investigator-drive study investigating the efficacy of liver transplantation after successful downstaging/disease control of unresectable perihilar cholangiocarcinoma using chemotherapy +/- immunotherapy and stereotactic body radiation therapy (SBRT).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Diagnosis of unresectable peripheral cholangiocarcinoma arising one centimeter or more above the superior pancreatic margin, with tumor diameter ≤ 3 cm, diagnosed by:

• Transcatheter biopsy or brush cytology

• CA-19.9 \> 100 mg/ml and/or a mass on cross-sectional imaging with a malignant appearing stricture on cholangiography

• Biliary ploidy by FISH with a malignant appearing stricture on cholangiography

• Age between 18 years and 70 years

• Absence of intra- and extrahepatic metastases

• Absence of lymph-nodal metastases at any site

• Biliary stenting of all liver districts

• No contraindications to liver transplantation

• No concomitant malignancies or history of other malignancies in the previous 5 years

• Written informed consent

Locations
Other Locations
Italy
Fondazione IRCCS Istituto Nazionale Tumori di Milano
RECRUITING
Milan
Contact Information
Primary
Vincenzo Mazzaferro, MD, PhD
vincenzo.mazzaferro@istitutotumori.mi.it
0223902760
Time Frame
Start Date: 2025-06-01
Estimated Completion Date: 2030-01-01
Participants
Target number of participants: 8
Treatments
Transplant
Patients with liver-limited unresectable perihilar cholangiocarcinoma with no other non-oncological contraindication to liver transplantation
Sponsors
Leads: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

This content was sourced from clinicaltrials.gov